Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of [14C]SH-1028 in Healthy Chinese Males
NCT04810533Phase 1Completed
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- May 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rilertinib in non-small cell lung cancer (NSCLC), sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd. Primary endpoints: Percentage of radioactive dose recovered in blood at Day 15, Percentage of radioactive dose recovered in urine and feces at Day 15 and 3 more. Started May 2020; status: completed.
02
Drugs
rilertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04810533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04810533.